Waystar Considers Sale Amidst Market Challenges

Waystar, a prominent healthcare software provider, is reportedly evaluating strategic alternatives, including the possibility of a sale, according to sources familiar with the matter. This move comes two years after the company's public listing in New York. The Lehi, Utah, and Louisville, Kentucky-based company has engaged investment bank Evercore to assist with the process, as confirmed by two individuals who requested anonymity due to the confidentiality of the discussions.

Market Pressures Influence Strategy

The company's valuation has declined significantly, dropping to approximately $4.8 billion following a 24% decrease in its share price this year amidst broader software sector sell-offs. Originally, Waystar positioned itself as a technology enterprise focused on automating healthcare administrative tasks, aiming for higher valuations akin to those of tech companies. Despite initial investor enthusiasm, which propelled its shares from $20 to a peak of $45 in 2025, recent concerns over potential disruptions from artificial intelligence have placed pressure on the stock.

Background and Ownership

Waystar was established in 2017 through the merger of Zirmed and Navicure, two healthcare revenue management firms. The company was taken public in 2024 by major investors, including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%, as per LSEG data. None of these stakeholders have commented on the current strategic review.

Future Prospects

While Waystar's strategic review is at an early stage and plans could change, the exploration of a sale may test investor interest in the software sector's recovery. The outcome of this process will be closely watched as it may signal broader trends in the valuation and market dynamics of healthcare technology companies.